NCT03395496

Brief Summary

The aim of this study is to compare two pulpotomy medicaments in primary molars clinically.A total of 200 primary molars with deep caries were treated with two different pulpotomy medicaments (Mineral Trioxide Aggregate and BiodentineTM) in this study. The inclusion criteria for tooth selection were no clinical and radiographic evidence of pulp pathology. During 36 months of follow-up at 3-month intervals, clinical and radiographic success and failures were recorded.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for early_phase_1

Timeline
Completed

Started May 2013

Typical duration for early_phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2013

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2016

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2016

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

December 26, 2017

Completed
15 days until next milestone

First Posted

Study publicly available on registry

January 10, 2018

Completed
Last Updated

January 10, 2018

Status Verified

January 1, 2018

Enrollment Period

3 years

First QC Date

December 26, 2017

Last Update Submit

January 3, 2018

Conditions

Keywords

pulpotomypediatric dentistryprimary molars

Outcome Measures

Primary Outcomes (1)

  • Total success rate

    12 months after pulpotomy treatment

Secondary Outcomes (1)

  • Total success rate

    24 months after pulpotomy treatment

Other Outcomes (1)

  • Total success rate

    36 months after pulpotomy treatment

Study Arms (2)

Biodentine

EXPERIMENTAL

Dental materials

Drug: BiodentineDrug: ProRoot (Aggregate)

ProRoot MTA

EXPERIMENTAL

Dental Materials

Drug: BiodentineDrug: ProRoot (Aggregate)

Interventions

Biodentine pulpotomy agent

Also known as: 77509635
BiodentineProRoot MTA

ProRoot MTA pulpotomy agent

Also known as: 75896452
BiodentineProRoot MTA

Eligibility Criteria

Age7 Years - 15 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • no clinical and radiographic evidence of pulp pathology,
  • no clinical and radiographic symptoms,
  • no history of spontaneous pain and tenderness,
  • no percussion, swelling or sinus tracts and pathologic mobility.

You may not qualify if:

  • any clinical or radiographic evidence of pulp degeneration (spontaneous or nocturnal tooth pain, tenderness to percussion, pathological mobility, internal or external root resorption, swelling or fistula, widened periodontal ligament (PDL)
  • furcal or periapical radiolucency teeth requiring more than 5 minutes to achieve hemostasis during clinical procedure.
  • without permanent successor

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istanbul University

Istanbul, 34093, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Dental Caries

Interventions

tricalcium silicateTheraCal

Condition Hierarchy (Ancestors)

Tooth DemineralizationTooth DiseasesStomatognathic Diseases

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 26, 2017

First Posted

January 10, 2018

Study Start

May 1, 2013

Primary Completion

May 1, 2016

Study Completion

May 30, 2016

Last Updated

January 10, 2018

Record last verified: 2018-01

Locations